Drug Trial Radar · NCT07281027
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
438
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Mar 31, 2030
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus). NORSE causes continuous seizures in previously healthy children and adults and does not respond to standard treatments. It often leads to long-term disability or death. Doctors currently use anakinra and tocilizumab as second-line treatments when first-line therapies fail, but there is no clear evidence showing which drug works better or when it should be given. This study aims to answer those questions. The study will enroll patients across 33 hospitals in the United States, Canada, Europe, and Asia. It includes two groups: 1. Randomized Cohort Patients will be randomly assigned to receive either anakinra or tocilizumab within the first 7 days of their illness. Only patients whose doctors were already planning to use one of these medications as part of standard care will be eligible for randomization. Researchers will monitor their recovery and compare outcomes between the two treatments. 2. Observational Cohort Patients who cannot be randomized-usually because they were diagnosed too late-will still be followed to study how the timing of treatment affects recovery. Participants will: * Receive one of the two medications (depending on their group assignment). * Take part in follow-up assessments over the course of one year, including medical evaluations and surveys. Some participants may be followed annually beyond one year. * Optionally participate in a 60-minute interview to share their or their caregiver's experience with NORSE.
Conditions
- New Onset Refractory Status Epilepticus
- New-Onset Refractory Status Epilepticus
- Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
AnakinraDrug
SOC will be followed , Suggested Dose: 10 mg/kg/day IV, divided into 4 daily doses (q6h) Maximum dose: 400 mg/day
TocilizumabDrug
SOC will be followed, Suggested Dose: If \<30 kg: 12 mg/kg IV once every 2 weeks If ≥30 kg: 8 mg/kg IV once every 2 weeks Maximum dose: 800 mg per dose
Standard medical treatmentOther
For patients who could not be randomized by day 7, standard clinical care will be followed and patients will be followed prospectively and observationally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glasgow Outcome Scale - Extended (GOS-E)Time frame: 12 months
Locations
33 sites in 7 countries. Site status is shown where the registry gives one.
Barrow Institute
Phoenix, Arizona
Children's Hospital Colorado
Aurora, Colorado
Yale New Haven Hospital
New Haven, Connecticut
Children's National (DC)
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
University of Chicago
Chicago, Illinois
Northwestern University
Evanston, Illinois
Mass General (MGH)
Boston, Massachusetts
Beth Israel Deaconess
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
University of Nebraska
Lincoln, Nebraska
New York University
New York, New York
Columbia University
New York, New York
Mount Sinai (NY)
New York, New York
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Children's Hospital Philadelphia (CHOP)
Philadelphia, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Baylor/Texas Children's
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Western University
London, Canada
Hospital for Sick Children
Toronto, Canada
Salpêtrière
Paris, France
University of Modena
Modena, Italy
Seoul National University Hospital
Seoul, South Korea
Karolinska Institute
Stockholm, Sweden
Great Ormond Street Hospital
London, United Kingdom
King's College
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.